中国科学院生物与化学交叉研究中心

设为首页 中文版

研究团队

您的位置:首页 > 研究团队 > 谭立课题组
发表文章

发表论文(#贡献相同):

1.     Tan L#, Akahane K#,McNally R, Reyskens KMSE, Ficarro SB, Liu S, Herter-Sprie GS, Koyama S,Pattison MJ, Labella K, Johannessen L, Akbay EA, Wong KK, Frank DA, Marto JA,Look TA, Arthur JSC, Eck MJ, Gray NS. Development of Selective Covalent JanusKinase 3 Inhibitors. J Med Chem. 2015, 58(16):6589-606.


2.     Tan L#, Wang J#,Tanizaki J#, Huang Z#, Aref AR#, Rusan M, ZhuSJ, Zhang Y, Ercan D, Liao RG, Capelletti M, Zhou W, Hur W, Kim N, Sim T,Gaudet S, Barbie DA, Yeh JR, Yun CH, Hammerman PS, Mohammadi M, Jänne PA, GrayNS. Development of covalent inhibitors that can overcomeresistance to first-generation FGFR kinase inhibitors.Proc Natl Acad SciU S A. 2014, 111(45):E4869-77.


3.     Tan L, Nomanbhoy T, Gurbani D,Patricelli M, Hunter J, Geng J, Herhaus L, Zhang J, Pauls E, Ham Y, Choi HG,Xie T, Deng X, Buhrlage SJ, Sim T, Cohen P, Sapkota G, Westover KD, Gray NS. Discovery of type II inhibitors of TGFβ-activated kinase 1(TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2).J Med Chem. 2015,58(1):183-96.


4.     Tan L, Ma D. Total synthesis ofSalinamide A: A Potent Anti-inflammatory Bicyclic Depsipeptide.Angew Chem In Ed.2008, 47(19), 3614-7.


5.     Terai H#, TanL#, Beauchamp EM, Hatcher JM, Liu Q, Meyerson M, Gray NS andHammerman PS. Characterization of DDR2 inhibitors for the treatment of DDR2mutated non-small cell lung cancer. ACSChem Biol.2015, 10(12):2687–96.


6.     Huang Z#, TanL#, Wang H, Liu Y, Blais S, Deng J, Neubert TA, Gray NS, Li X,Mohammadi M. DFG-out mode of inhibition by an irreversible type-1inhibitor capable of overcoming gate-keeper mutations in FGF receptors.ACS Chem Biol.2015 10(1):299-309.


7.     Kim HG#, TanL#, Weisberg EL#, Liu F#, Canning P#, Choi HG#, Ezell SA, Wu H,Zhao Z, Wang J, Mandinova A, Griffin JD, Bullock AN, Liu Q, Lee SW, Gray NS. Discovery of a Potent and Selective DDR1 Receptor TyrosineKinase Inhibitor.ACS Chem Biol.2013, 8(10):2145-50.


8.     Yang G, Buhrlage S, Tan L, Liu X, Chen J, Xu L, TsakmaklisN, Chen JG, Patterson CJ, Brown JR, Castillo JJ, Zhang W, Zhang X, Liu S, CohenP, Hunter ZR, Gray NS, Treon SP. HCK is a survival determinant transactivated by mutatedMYD88, and a direct target of ibrutinib.Blood. 2016,127(25):3237-52.


9.     AmatoKR, Wang S#, Tan L#,Hastings AK, Song W, Lovly CM, Meador CB, Ye F, Lu P, Balko JM, Colvin DC,Cates JM, Pao W, Gray NS, Chen J. EPHA2 Blockade Overcomes Acquired Resistance to EGFRKinase Inhibitors in Lung Cancer.CancerRes. 2016,76(2):305-18.


10. HoCM, Donovan-Banfield IZ, Tan L,Zhang T, Gray NS, Strang BL. Inhibition of IKKα by BAY61-3606 RevealsIKKα-Dependent Histone H3 Phosphorylation in Human Cytomegalovirus InfectedCells.PLoS One. 2016, 11(3):e0150339.


11. Matthews JM, Bhatt S, Patricelli MP, Nomanbhoy TK,Jiang X, Natkunam Y, Gentles AJ, Martinez E, Zhu D, Chapman JR, Cortizas E,Shyam R, Chinichian S, Advani R, Tan L,Zhang J, Choi HG, Tibshirani R, Buhrlage SJ, Gratzinger D, VerdunR, Gray NS, Lossos IS.Pathophysiological significance and therapeutictargeting of germinal center kinase in diffuse large B-cell lymphoma.Blood. 2016, pii: blood-2016-02-696856.


12. Miao B, Ji Z, Tan L,Taylor M, Zhang J, Choi HG, Frederick DT, Kumar R, Wargo JA, Flaherty KT, GrayNS, Tsao H. EPHA2 Is a Mediator of Vemurafenib Resistance and a NovelTherapeutic Target in Melanoma.CancerDiscov. 2015, 5(3):274-87.


13. Moccia M, Liu QS, Guida T, Federico G, Brescia A, Zhao , ChoiHG, Deng X, Tan L, Wang J, BillaudM, Gray NS, Carlomagno F, Santoro M. Identification of novel small moleculeinhibitors of oncogenic RET kinase. PLoSOne. 2015, 5;10(6):e0128364.


14. Amato KR, Wang S, Hastings AK, Youngblood VM, Santapuram PR,Chen H, Cates JM, Colvin DC, Ye F, Brantley-Sieders DM, Cook RS, Tan L, Gray NS, Chen J. Genetic and pharmacologic inhibition of EPHA2 promotesapoptosis in NSCLC.J Clin Invest. 2014, 124(5):2037-49.


15. Wang J, Mikse O, Liao RG, Li Y, Tan L, Janne PA, Gray NS, Wong KK, Hammerman PS. Ligand-associated ERBB2/3activation confers acquired resistance to FGFR inhibition in FGFR3-dependentcancer cells. Oncogene. 2014,34(17):2167-2177..


16. Beauchamp EM, Woods BA, Dulak AM, Tan L, Xu C, Gray NS, Bass AJ, Wong KK, Meyerson M, Hammerman PS. Acquired resistance to dasatinib in lung cancer cell linesconferred by DDR2 gatekeeper mutation and NF1 loss.Mol Cancer Ther. 2014,13(2):475-82.


17. Canning P, Tan L,Chu K, Lee SW, Gray NS, Bullock AN. Structural mechanisms determining inhibition of thecollagen receptor DDR1 by selective and multi-targeted type II kinaseinhibitors.J Mol Biol.2014, 426(13):2457-70.


18. Pauls E, Shpiro N, Peggie M, Young ER, Sorcek RJ, Tan L, Choi HG, Cohen P. Essential role for IKKβ in production of type 1interferons by plasmacytoid dendritic cells.J Biol Chem. 2012,287(23):19216-28.


19. Dzamko N, Inesta-Vaquera F, Zhang J, Xie C, Cai H, Arthur S, Tan L, Choi H, Gray NS, Cohen P,Pedrioli P, Clark K, Alessi DR. The IkappaB kinase family phosphorylates the Parkinson's diseasekinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling.PLoS One. 2012,7(6):e39132.


20. Kwiatkowski N, Deng X, Wang J, Tan L, Villa F, Santaguida S, Huang HC, Mitchison T, Musacchio A, NS. Selective aurora kinase inhibitors identified using ataxol-induced checkpoint sensitivity screen.ACS Chem Biol. 2012,7(1), 185-96.


21. Han S, Pan H, Zhang J, TanL, Ma D, Yuan J, Wu J. Identification of a small molecule activator of novel PKCsfor promoting glucose-dependent insulin secretion.Cell Res. 2011, 21(4), 588-99.

 

申请专利:

1.    Gray NS andTan L. JANUS KINASE INHIBITORS AND USES THEREOF. WO/2015/164614.


2.    Gray NS andTan L.HYDROPHOBICALLYTAGGED JANUS KINASE INHIBITORS AND USES THEREOF. WO/2015/164604.


3.    Treon SP, Gray NS, Buhrlage SJ, Tan L and Yang G. METHODS TO TREAT LYMPHOPLASMACYTICLYMPHOMA. WO/2015/089479.


4.    Treon SP, Gray NS, Buhrlage SJ, Tan L and Yang G. METHODS TO TREAT LYMPHOPLASMACYTICLYMPHOMA. WO/2015/089481.


5.    Gray NS, Choi HG andTan L.KINASE INHIBITORS FOR THE TREATMENT OF DISEASE. WO/2015/006492.

 

中国科学院生物与化学交叉研究中心 版权所有 电话:021-54925106/50800885
地址:上海市徐汇区零陵路345号君谋楼/浦东张江高科技园区秋月路26号6号楼 技术支持:FLAT